Explore GEN family of websites, social media experiences, blogs and more.

Unleashing ideas.
Strengthening startups.

Back to search results
    Date submitted
  • 31-Mar-2017

MMP Biopharma, Inc.


Early stage biotech company developing therapeutics focused on serving FAU’s Healthy Aging Pillar. MMP Biopharma, Inc. is dedicated to delivering innovative solutions for people with diseases characterized by the degradation of collagen and is proud to present the development of first-in-class compound targeting collagen degradation in osteoarthritis.

Additional Questions

Who is your customer?

People affected by osteoarthritis will benefit from MMP Biopharma's product. Osteoarthritis (OA) is currently an incurable and chronic condition affecting 54.4 million people in the United States. OA risk factors: Age — Advancing age is one of the strongest risk factors for OA. The condition rarely occurs in people younger than age 40, but at least 80 percent of people over age 55 have some x-ray evidence of the disorder. However, not all people with arthritis on an x-ray have joint pain or other joint problems. Gender — For unknown reasons, women are between two and three times more likely than men to develop OA. Obesity — People who are obese are at high risk of developing OA. Weight loss may reduce this risk. Occupation — OA of the knee has been linked to certain occupations that require frequent squatting and kneeling, including cotton processing, dock work, shipyard work, and carpentry. OA of the hip has been linked to farm work, construction work, and other activities that require heavy lifting, prolonged standing, or walking several miles each day. Sports — The risk of OA is increased in those who participate in certain sports, including wrestling, boxing, pitching in baseball, cycling, parachuting, cricket, gymnastics, ballet dancing, soccer, and football; by contrast, running does not appear to increase the risk of OA.

What problem does this idea/product solve or what market need does it serve?

Current OA treatments only address symptoms and pain management. MMP Biopharma, Inc. is developing a drug that aims at stopping the progression of osteoarthritis and bringing back the quality of life of affected patients.

What attributes will make this idea/product successful? Why do you believe that those features will create success?

At this time the only products that have shown to slow down the progression of OA in Phase III clinical trials are injectable and are difficult and expensive to manufacture. MMP Biopharma, Inc. is aiming at the development of an oral formulation of our current product. Our product will be easily administered to patients and can be produced very economically at large scale.

Explain how you (your team) will execute to make this idea/product successful? What gives you (your team) an advantage over others already in the market or new to this market?

MMP Biopharma's founders discovered and developed the product to target the disease in a very different way that other products work. Our Board members have decades of combined experience in bringing drugs through clinical trials and to the market.